GLP-1/amylin receptor (dual)

Class

Dual GLP-1/amylin receptor agonist

The GLP-1/amylin receptor dual agonist mechanism targets two separate but complementary hormone-signaling systems involved in appetite and glucose regulation. GLP-1 (glucagon-like peptide-1) is an intestinal hormone that, upon binding its receptor, enhances glucose-dependent insulin release, slows stomach emptying, and signals satiety to the brain. Amylin is a hormone co-released with insulin from pancreatic beta cells that acts through its own receptor to slow gastric emptying, suppress glucagon secretion, and promote fullness through a distinct brain pathway. Because these two systems influence appetite and digestion through different neural circuits, activating both receptors at once can produce satiety and weight-reduction effects that are more pronounced than activating either pathway alone. This dual approach is being explored as a strategy for treating obesity and type 2 diabetes, conditions where excess caloric intake, impaired insulin secretion, and abnormal glucose control are central features. By engaging complementary mechanisms rather than intensifying a single one, dual agonism aims to achieve greater metabolic benefit, potentially at more moderate doses of either individual activity, while still working through pathways the body already uses to regulate hunger and blood sugar.